Evidence map›Paper›PMID 42246034›Full record

ArticleFrontiers in systems biology2026

Toward the genetic landscape of prostate cancer in India: insights from whole-exome and low-pass whole-genome sequencing of formalin-fixed paraffin-embedded tumor tissues.

Soham Biswas, Bhargavi Rajarathinam, Barkha Khilwani, Gaurav Jalendra, Devendra Sharma, Maneesh Vijavargiya, Rajaguru Aradhya, Abdul S Ansari, Nidhi Shukla, Gyaneshwer Chaubey and 3 more

Abstract read
In one paragraph

Article in Frontiers in systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Soham Biswas *Department of Biosciences, Manipal University Jaipur, Jaipur, India.
Bhargavi Rajarathinam *Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Clappana, Kerala, India.
Barkha KhilwaniThe CA Prostate Consortium of India (CAPCI), Bioclues.org, Hyderabad, India.
Gaurav JalendraThe CA Prostate Consortium of India (CAPCI), Bioclues.org, Hyderabad, India.
Devendra SharmaThe CA Prostate Consortium of India (CAPCI), Bioclues.org, Hyderabad, India.
Maneesh VijavargiyaThe CA Prostate Consortium of India (CAPCI), Bioclues.org, Hyderabad, India.
Rajaguru AradhyaAmrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Clappana, Kerala, India.
Abdul S AnsariThe CA Prostate Consortium of India (CAPCI), Bioclues.org, Hyderabad, India.
Nidhi ShuklaThe CA Prostate Consortium of India (CAPCI), Bioclues.org, Hyderabad, India.
Gyaneshwer ChaubeyThe CA Prostate Consortium of India (CAPCI), Bioclues.org, Hyderabad, India.
Nirmal Kumar LohiyaThe CA Prostate Consortium of India (CAPCI), Bioclues.org, Hyderabad, India.
Prashanth SuravajhalaDepartment of Biosciences, Manipal University Jaipur, Jaipur, India.
CA Prostate Consortium of India (CAPCI)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Prostate cancer (PCa) is a leading malignancy in men, with global incidence showing geographical variations. In India, PCa burden is increasing, especially in urban areas and for men over 50 years of age. Our collaborative effort with the Cancer Prostate Consortium of India (CAPCI) aims to map the genetic landscape of PCa in India, investigate somatic mosaicism, and assess the utility of low-pass whole-genome sequencing (LP-WGS) in determining PCa pathogenesis. Materials and methods: We performed variant calling using the CONVEX pipeline on whole-exome sequencing (WES) and LP-WGS samples, categorized by tumor grades. Results and discussion: ClinVar validation of WES variants identified 12 consensus somatic variants mapped to gnomAD, with 11 being pathogenic, likely pathogenic, or variants of uncertain significance (VUS). We also screened 956 germline variants common to at least two of the 49 samples, identifying 88 common variants, including missense and small InDels. Common and unique somatic variants were found in APC, BRAF, ATM, TP53, SMAD4 and CHEK2 genes. Four of these (rs62619935, rs202160435, rs121913343, and rs141568342) are extremely rare (MAF <= 0.001), seven single nucleotide variants (SNVs) are novel, with four being VUS. Pathogenic somatic variants in higher Gleason score samples (4+4 and 4+3) were homozygous, while benign prostatic hyperplasia (BPH) samples with lower Gleason scores were heterozygous, aligning with population stratification. Whereas the rs1042522 variant in the TP53 gene, with a gnomAD MAF of nearly 38%, was a common somatic SNV, we also identified distinct CAG repeat mosaicism associated with PCa risk.

Indexed as

genome sequecingprostate cancersomatic mutationsystems genomicswhole exome sequencing

Identifiers

PMID42246034
PMCPMC13229647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.